Abstract:Chronic inflammation is now recognized as one of the major risk factors and molecular hallmarks of chronic prostatitis, benign prostatic hyperplasia (BPH), and prostate tumorigenesis. However, the molecular mechanisms by which chronic inflammation signaling contributes to the pathogenesis of these prostate diseases are poorly understood. Previous efforts to therapeutically target the upstream (e.g., TLRs and IL1-Rs) and downstream (e.g., NF-κB subunits and cytokines) inflammatory signaling molecules in people with these conditions have been clinically ambiguous and unsatisfactory, hence fostering the recent paradigm shift towards unraveling and understanding the functional roles and clinical significance of the novel and relatively underexplored inflammatory molecules and pathways that could become potential therapeutic targets in managing prostatic diseases. In this review article, we exclusively discuss the causal and molecular drivers of prostatitis, BPH, and prostate tumorigenesis, as well as the potential impacts of microbiome dysbiosis and chronic inflammation in promoting prostate pathologies. We specifically focus on the importance of some of the underexplored druggable inflammatory molecules, by discussing how their aberrant signaling could promote prostate cancer (PCa) stemness, neuroendocrine differentiation, castration resistance, metabolic reprogramming, and immunosuppression. The potential contribution of the IL1R-TLR-IRAK-NF-κBs signaling molecules and NLR/inflammasomes in prostate pathologies, as well as the prospective benefits of selectively targeting the midstream molecules in the various inflammatory cascades, are also discussed. Though this review concentrates more on PCa, we envision that the information could be applied to other prostate diseases. In conclusion, we have underlined the molecular mechanisms and signaling pathways that may need to be targeted and/or further investigated to better understand the association between chronic inflammation and prostate diseases.

Inflammatory mediators in the development and progression of benign prostatic hyperplasia

Urinary Microbiota In Patients With Prostate Cancer And Benign Prostatic Hyperplasia

The role of prostatic inflammation in the development and progression of benign and malignant diseases

The Role of Inflammation in Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) and Its Potential Impact on Medical Therapy

[Inflammation and benign prostatic hyperplasia: cause or consequence?]

Immune Cell Proinflammatory Microenvironment and Androgen-Related Metabolic Regulation During Benign Prostatic Hyperplasia in Aging

Inflammation in Prostatic Hyperplasia and Carcinoma—Basic Scientific Approach

Effects of inflammatory prostatitis on the development and progression of benign prostatic hyperplasia: A literature review

Growth factors in benign prostatic hyperplasia: Basic science implications

Benign prostatic hyperplasia – what do we know?

The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer

The Human Microbiome and Benign Prostatic Hyperplasia: Current Understandings and Clinical Implications

Mechanism of Androgen-Independent Stromal Proliferation in Benign Prostatic Hyperplasia

Chronic inflammation promotes proliferation in the prostatic stroma in rats with experimental autoimmune prostatitis: study for a novel method of inducing benign prostatic hyperplasia in a rat model

Review of the Roles and Interaction of Androgen and Inflammation in Benign Prostatic Hyperplasia

Benign prostatic hyperplasia - A novel autoimmune disease with a potential therapy consequence?

Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review

The role of gut microbiota in prostate inflammation and benign prostatic hyperplasia and its therapeutic implications

The Etiology and Pathogenesis of Benign Prostatic Hyperplasia: The Roles of Sex Hormones and Anatomy

Elevated Anaphylatoxin C3a in Expressed Prostatic Secretion Correlates with Prostatic Inflammation Extent in Benign Prostatic Hyperplasia

Metabolic Syndrome and Benign Prostatic Hyperplasia: Evidence of a Potential Relationship, Hypothesized Etiology, and Prevention